The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The potential of Tenascin C in the tumor-nerve microenvironment to enhance perineural invasion and correlate with locoregional recurrence-related poor prognosis in pancreatic ductal adenocarcinoma.
 
Satoru Furuhashi
No Relationships to Disclose
 
Takanori Sakaguchi
Honoraria - Eisai; Eisai; Eisai; Eisai; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Ryuta Muraki
No Relationships to Disclose
 
Ryo Kitajima
No Relationships to Disclose
 
Mayu Fukushima
No Relationships to Disclose
 
Makoto Takeda
No Relationships to Disclose
 
Yoshifumi Morita
No Relationships to Disclose
 
Hirotoshi Kikuchi
Honoraria - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Covidien; Covidien; Covidien; Covidien; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Pfizer; Pfizer; Pfizer; Pfizer
Consulting or Advisory Role - Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin; Bayer Yakuhin
 
Mitsutoshi Setou
No Relationships to Disclose
 
HIROYA TAKEUCHI
Honoraria - Abbott Japan; Abbott Japan; Abbott Japan; Abbott Japan; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Covidien; Covidien; Covidien; Covidien; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; EA Pharma; EA Pharma; EA Pharma; EA Pharma; Ethicon; Ethicon; Ethicon; Ethicon; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Kaken Pharmaceutical; Lilly; Lilly; Lilly; Lilly; Medicon; Medicon; Medicon; Medicon; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Nihonkayaku; Nihonkayaku; Nihonkayaku; Nihonkayaku; Olympus; Olympus; Olympus; Olympus; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Otsuka; Otsuka; Otsuka; Otsuka; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Nihonkayaku (Inst); Nihonkayaku (Inst); Nihonkayaku (Inst); Nihonkayaku (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Tsumura & Co. (Inst); Tsumura & Co. (Inst); Tsumura & Co. (Inst); Tsumura & Co. (Inst)